# BioWorld * **Definition:** BioWorld is a news source that provides in-depth coverage and analysis of the biotechnology and pharmaceutical industries, including updates on research, regulatory developments, and market trends. * **Taxonomy:** Key Sources / Healthcare Publications / BioWorld ## News * Selected news from the source **BioWorld**, for healthcare technology leaders * 1.2K news items are in the system for this source * Posts have been filtered for tech-related keywords | Date | Title | Topics | | --- | --- | --- | | 5/11/2025 | [**Integrating AI-based neoantigen prediction and APC-targeted delivery to enhance cancer immunotherapy**](https://www.bioworld.com/articles/720080-integrating-ai-based-neoantigen-prediction-and-apc-targeted-delivery-to-enhance-cancer-immunotherapy) | [[Cancer Immunotherapy]] | | 4/22/2025 | [**US HHS axes women's health research**](https://www.bioworld.com/articles/719479-us-hhs-axes-womens-health-research) | [[Maternal Health]]; [[Public Health]]; [[Neurology]] | | 4/9/2025 | [**Other news to note for April 8, 2025 - BioWorld**](https://www.bioworld.com/articles/718877-other-news-to-note-for-april-8-2025) | [[Biosimilars]]; [[Biopharma]]; [[Data Analysis]] | | 3/23/2025 | [**Congress revisits the Medicare radiation oncology rate controversy**](https://www.bioworld.com/articles/718205-congress-revisits-the-medicare-radiation-oncology-rate-controversy) | [[Neurology]]; [[Radiation Oncology]]; [[Oncology]] | | 3/22/2025 | [**AI legislation advances in US states as Washington dithers - BioWorld**](https://www.bioworld.com/articles/718004-ai-legislation-advances-in-us-states-as-washington-dithers) | [[Biopharma]]; [[Compliance]]; [[Health]] | | 3/15/2025 | [**Gene therapy efforts active, despite low Bluebird, 2seventy bids - BioWorld**](https://www.bioworld.com/articles/718258-gene-therapy-efforts-active-despite-low-bluebird-2seventy-bids) | [[Medicaid]]; [[Artificial Intelligence]]; [[Endocrinology]] | | 3/14/2025 | [**Oz promises AI, innovation, lower drug prices if confirmed to lead CMS - BioWorld**](https://www.bioworld.com/articles/718252-oz-promises-ai-innovation-lower-drug-prices-if-confirmed-to-lead-cms) | [[AI in Pediatric Care]]; [[Womens Health]]; [[AI in Mental Health]] | | 1/14/2025 | [**JPM: Sling's small molecule has success in thyroid eye disease - BioWorld**](https://www.bioworld.com/articles/716268-jpm-slings-small-molecule-has-success-in-thyroid-eye-disease) | [[AI for Medical Device]]; [[Regulatory Approval]]; [[Regulatory Approvals]] | | 12/8/2024 | [**Digital health - Articles - Page 9 - BioWorld**](https://www.bioworld.com/articles/topic/350&ved=2ahUKEwid78LLjPn_AhUQpZUCHRM8AGsQFnoECDgQAg&usg=AOvVaw2lMn39TTU7PQS6NPHMoJoU?page=9) | [[AI in Recruitment]]; [[Electronic Medical Record]]; [[Healthtech Innovation Hub]] | | 10/22/2024 | [**By the numbers: US leads charge of cell and gene therapies - BioWorld**](https://www.bioworld.com/articles/713702-by-the-numbers-us-leads-charge-of-cell-and-gene-therapies) | [[Healthcare Access Disparities]]; [[Healthcare Affordability]]; [[Synthetic Biology]] | | 10/21/2024 | [**Other news to note for Oct. 21, 2024 - BioWorld**](https://www.bioworld.com/articles/713593-other-news-to-note-for-oct-21-2024) | [[Biomedical Engineering]]; [[Bioinformatics]]; [[Synthetic Biology]] | | 10/21/2024 | [**Lanova raises $42M series C round to advance lead programs - BioWorld**](https://www.bioworld.com/articles/713682-lanova-raises-42m-series-c-round-to-advance-lead-programs) | [[Clinical Trial Design]]; [[Biomedical Science]]; [[FDA Approvals]] | | 10/18/2024 | [**After delays, Abbvie wins FDA approval for Parkinson's treatment - BioWorld**](https://www.bioworld.com/articles/713515-after-delays-abbvie-wins-fda-approval-for-parkinsons-treatment) | [[Hyper-Personalized Medicine]]; [[Decentralized Clinical Trials]]; [[Precision Medicine]] | | 10/11/2024 | [**FDA gives early approval to Genentech's first-line breast cancer treatment - BioWorld**](https://www.bioworld.com/articles/713287-fda-gives-early-approval-to-genentechs-first-line-breast-cancer-treatment) | [[Clinical Data]]; [[Cancer Treatment]]; [[AI in Medicine]] | | 10/10/2024 | [**Other news to note for Oct. 10, 2024 - BioWorld**](https://www.bioworld.com/articles/713284-other-news-to-note-for-oct-10-2024) | [[Biopharma]]; [[Strategic Partnerships]]; [[Collaboration]] | | 10/9/2024 | [**Advancing gene therapy for kidney disease, Purespring adds £80M - BioWorld**](https://www.bioworld.com/articles/713256-advancing-gene-therapy-for-kidney-disease-purespring-adds-80m) | [[Biopharma]]; [[Drug Discovery]]; [[Gene Therapy]] | | 10/3/2024 | [**US CMS sets playing field for next round of Rx price negotiations - BioWorld**](https://www.bioworld.com/articles/713192-us-cms-sets-playing-field-for-next-round-of-rx-price-negotiations) | [[Healthcare Communication]]; [[Engineering]]; [[Collaboration]] | | 9/24/2024 | [**Financings for September 24, 2024 - BioWorld**](https://www.bioworld.com/articles/712456-financings-for-september-24-2024) | [[Corporate IT]]; [[Strategy]]; [[Healthcare Cloud Computing]] | | 9/17/2024 | [**Australia's HTA consultation wraps up with 50 recommendations - BioWorld**](https://www.bioworld.com/articles/712601-australias-hta-consultation-wraps-up-with-50-recommendations) | [[AI in Medicine]]; [[Technical Assessment]]; [[Health]] | | 8/22/2024 | [**UK clears Leqembi for Alzheimer's; NHS unlikely to embrace cost - BioWorld**](https://www.bioworld.com/articles/711726-uk-clears-leqembi-for-alzheimers-nhs-unlikely-to-embrace-cost) | [[AI in Medicine]]; [[Collaboration]]; [[Big Data in MedTech]] | | 8/8/2024 | [**Neurology/psychiatric**](https://www.bioworld.com/articles/topic/256-neurology-psychiatric?page=8) | [[Medical Research]]; [[FDA Approvals]]; [[Regulatory Approval]] | | 7/31/2024 | [**Jiuyuan, Biokin, Transthera file for Hong Kong IPOs in July - BioWorld**](https://www.bioworld.com/articles/710795-jiuyuan-biokin-transthera-file-for-hong-kong-ipos-in-july) | [[Biopharma]]; [[Health]]; [[Data Analysis]] | | 7/20/2024 | [**Australia looks to digital strategies for better elder care - BioWorld**](https://www.bioworld.com/articles/710504-australia-looks-to-digital-strategies-for-better-elder-care) | [[Mergers]]; [[Clinical AI]]; [[FDA Approvals]] | | 7/20/2024 | [**Artiva prices $167M IPO as its NK cell therapy advances - BioWorld**](https://www.bioworld.com/articles/710637-artiva-prices-167m-ipo-as-its-nk-cell-therapy-advances) | [[Health]]; [[Clinical Trial Design]]; [[Biopharma]] | | 7/19/2024 | [**SPAC market diminished but alive despite new SEC rules - BioWorld**](https://www.bioworld.com/articles/710702-spac-market-diminished-but-alive-despite-new-sec-rules) | [[Healthcare Communications]]; [[Mergers and Acquisitions]]; [[Healthcare Education]] | ## Recent Stories (Some LLM-derived content — please confirm with above primary sources) ### Topics Covered - **Funding Cuts Impacting Biopharma Research**: The Trump administration's cuts to university research budgets and NIH grants raise concerns about the future of biopharma research and the transition of research ideas into viable companies. - **Regulatory Challenges and Trade Policies**: Senator Amy Klobuchar opposes tariffs imposed by the Trump administration, citing regulatory challenges at the FDA and the need for improvements in the biopharma sector. - **Biopharma Financing Trends**: Biopharma funding has seen a significant decline, with a 71% drop in the first four months of 2025, while the sector continues to navigate a complex landscape of investments and deal values. - **Public Health Concerns**: Experts warn that budget cuts may undermine the CDC's ability to monitor and respond to infectious disease outbreaks, highlighting the importance of adequate funding for public health. - **Emerging Therapies and Innovations**: The article discusses advancements in gene therapy, immunotherapy, and the impact of AI in healthcare regulation, along with notable partnerships and funding activities in the biopharma sector. - **Diversity in Biotech Leadership**: A report indicates stagnation in female representation in C-suite positions within the biotech industry, raising concerns about diversity and inclusion efforts. - **Partnerships and Grants**: Various developments in the med-tech sector, including partnerships and grants from companies like Beyond Air, Circadian Health, and Guardant Health. - **Impact of U.S. Tariffs**: Recent U.S. tariffs have significantly impacted the med-tech industry, while biopharmaceuticals have avoided similar repercussions. - **Alzheimer's & Parkinson's Diseases Conference**: Insights shared by Lotte Bjerre Knudsen from Novo Nordisk at the conference in Vienna, contributing to neurodegenerative disease research discussions. - **Med-Tech Updates in Asia**: Updates on the med-tech landscape in Asia, featuring companies like Helius Medical, Instylla, and Labcorp. - **Cuts to Women's Health Research**: Significant cuts to women's health research funding by the U.S. Department of Health and Human Services, raising concerns among advocates. - **NIH Leadership Changes**: Jay Bhattacharya, the new director of the National Institutes of Health, addresses staff amidst challenges to NIH research initiatives. - **Broader Implications of Funding Cuts**: Criticism of funding cuts for women's health research and their potential negative impact on public health and women's health outcomes. - **MedicalTechnologyDevelopments**: Overview of advancements in medical technology, including digital data analysis, women's health, GLP-1 therapies in China, and the rise of obesity. - **ClinicalTrials**: Discussion on diversifying clinical trials to improve patient recruitment and retention across ethnic backgrounds. - **RegulatoryUpdates**: FDA's draft guidance on obesity drugs and sex-specific data in clinical trials, along with EMA's review of Novo Nordisk's semaglutide. - **FundingAndInvestments**: Various companies raising funds for innovative therapies, including Celosia Therapeutics and Verdiva Bio. - **MarketTrends**: Insights into the growing market for radiopharmaceuticals, biosimilars, and the impact of recent stock fluctuations in biotech companies. - **ResearchAdvancements**: Updates on Alzheimer's research, gene therapies, and new drug approvals, including stem cell therapies and CAR T-cell therapies. - **Biopharma Deals and Collaborations**: Updates on various deals, partnerships, and collaborations in the biopharma sector, including a significant research collaboration between Prime Medicine Inc. and Bristol Myers Squibb Co. ### Organizations Mentioned - **U.S. NIH**: The National Institutes of Health, a part of the U.S. Department of Health and Human Services, responsible for biomedical and public health research. - **FDA**: The U.S. Food and Drug Administration, a federal agency responsible for regulating food, drugs, and medical devices. - **CDC**: The Centers for Disease Control and Prevention, a national public health institute in the U.S. focused on disease control and prevention. - **Bioindustry Association (BIA)**: A trade association representing the biotechnology sector in the UK, focusing on promoting the interests of biotech companies. - **Valo Therapeutics Oy**: A Finnish cancer immunotherapy company focused on developing treatments for solid tumors. - **Adarx Pharmaceuticals**: A biopharmaceutical company specializing in small interfering RNA technology for therapeutic applications. - **Incyte Corp.**: A biopharmaceutical company focused on developing innovative medicines for cancer and other serious diseases. - **Beyond Air**: A company involved in med-tech developments. - **Circadian Health**: A company contributing to advancements in the med-tech sector. - **Guardant Health**: A med-tech company mentioned in the context of partnerships and grants. - **Novo Nordisk**: A company represented by Lotte Bjerre Knudsen at the Alzheimer's & Parkinson's Diseases Conference. - **Helius Medical**: A company featured in updates on the med-tech landscape in Asia. - **Instylla**: Another company highlighted in the latest med-tech news from Asia. - **Labcorp**: A company mentioned in the context of ongoing developments in the med-tech sector. - **U.S. Department of Health and Human Services (HHS)**: The government department responsible for cuts to women's health research funding. - **National Institutes of Health (NIH)**: The organization led by Jay Bhattacharya, facing challenges in research funding. - **BioWorld**: A publication providing insights into medical technology and biopharma developments. - **Athira Pharma Inc.**: Company settling allegations related to research misconduct. - **Sana Biotechnology Inc.**: Company focusing on type 1 diabetes research and reporting positive clinical trial results. - **Celosia Therapeutics Pty Ltd.**: Company raising funds for gene therapy development.